Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 9/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 1.00 |
| ▸ | JAK2 | O60674 | 4/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.74 |
| ▸ | TYK2 | P29597 | 1/20 | 0.74 |
| ▸ | INSR | P06213 | 4/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24255339 | 0.93 | TNK2 (0.87) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL16453379 | 0.93 | TNK2 (0.86) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL24255302 | 0.87 | ALK (0.77) | TNK2ALKSRCJAK2INSR | |
| SCHEMBL24255341 | 0.85 | TNK2 (0.82) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL26270588 | 0.85 | TNK2 (0.82) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL16447661 | 0.85 | TNK2 (1.00) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL30527283 | 0.85 | TNK2 (1.00) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL16447760 | 0.85 | TNK2 (1.00) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL16447662 | 0.85 | TNK2 (1.00) | TNK2ALKSRCJAK2ROS1 | |
| SCHEMBL26270554 | 0.85 | TNK2 (0.82) | TNK2ALKSRCJAK2ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2017023899-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | TNK2 3/4885ALK 372/4885SRC 380/4885 |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | TNK2 3/4885ALK 372/4885SRC 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.